Search Results - "Hendriks, Rianne J."

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score by Van Neste, Leander, Hendriks, Rianne J, Dijkstra, Siebren, Trooskens, Geert, Cornel, Erik B, Jannink, Sander A, de Jong, Hans, Hessels, Daphne, Smit, Frank P, Melchers, Willem J.G, Leyten, Gisèle H.J.M, de Reijke, Theo M, Vergunst, Henk, Kil, Paul, Knipscheer, Ben C, Hulsbergen-van de Kaa, Christina A, Mulders, Peter F.A, van Oort, Inge M, Van Criekinge, Wim, Schalken, Jack A

“…Abstract Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect clinically significant prostate cancer (PCa). Objective To…”
Get full text

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients by Hendriks, Rianne J., Dijkstra, Siebren, Smit, Frank P., Vandersmissen, Johan, Van de Voorde, Hendrik, Mulders, Peter F. A., van Oort, Inge M., Van Criekinge, Wim, Schalken, Jack A.

“…Background : Noninvasive biomarkers to guide personalized treatment for castration‐resistant prostate cancer (CRPC) are needed. In this study, we analyzed…”
Get full text

Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes by Hendriks, Rianne J, Dijkstra, Siebren, Jannink, Sander A, Steffens, Martijn G, van Oort, Inge M, Mulders, Peter F A, Schalken, Jack A

“…PCA3 and ERG are mRNA-based prostate cancer (PCa) specific biomarkers that can be detected in urine. However, urine is a complex substrate that can be…”
Get more information

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide by Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.

“…Two novel oral drugs that target androgen signaling have recently become available for the treatment of metastatic castration-resistant prostate cancer…”
Get full text

A urinary biomarker‐based risk score correlates with multiparametric MRI for prostate cancer detection by Hendriks, Rianne J., van der Leest, Marloes M. G., Dijkstra, Siebren, Barentsz, Jelle O., Van Criekinge, Wim, Hulsbergen‐van de Kaa, Christina A., Schalken, Jack A., Mulders, Peter F. A., van Oort, Inge M.

“…Background Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non‐invasive techniques for the detection of clinically significant…”
Get full text

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men by Hendriks, Rianne J., van der Leest, Marloes M. G., Israël, Bas, Hannink, Gerjon, YantiSetiasti, Anglita, Cornel, Erik B., Hulsbergen-van de Kaa, Christina A., Klaver, O. Sjoerd, Sedelaar, J. P. Michiel, Van Criekinge, Wim, de Jong, Hans, Mulders, Peter F. A., Crawford, E. David, Veltman, Jeroen, Schalken, Jack A., Barentsz, Jelle O., van Oort, Inge M.

“…Background Risk stratification in men with suspicion of prostate cancer (PCa) requires reliable diagnostic tests, not only to identify high-grade PCa, also to…”
Get full text

Cost‐effectiveness of a new urinary biomarker‐based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model by Dijkstra, Siebren, Govers, Tim M., Hendriks, Rianne J., Schalken, Jack A., Van Criekinge, Wim, Van Neste, Leander, Grutters, Janneke P.C., Sedelaar, John P. Michiel, Oort, Inge M.

“…Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score (SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for…”
Get full text

MP53-04 IDENTIFICATION OF HIGH-GRADE PROSTATE CANCER USING URINE-BASED MOLECULAR BIOMARKERS COMBINED WITH CLINICAL RISK FACTORS by Van Neste, Leander, Trooskens, Geert, Hendriks, Rianne J, Schalken, Jack, Van Criekinge, Wim

Get full text

MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION by Hendriks, Rianne J, Van Neste, Leander, Marloes, Mulders, Schalken, Jack A, Van Oort, Inge M

Get full text

Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker by Hendriks, Rianne J., Dijkstra, Siebren, Cornel, Erik B., Jannink, Sander A., de Jong, Hans, Hessels, Daphne, Smit, Frank P., Melchers, Willem J.G., Leyten, Gisèle, de Reijke, Theo M., Vergunst, Henk, Kil, Paul, Knipscheer, Ben C., de Kaa, Christina A. Hulsbergen-van, Mulders, Peter F.A., van Oort, Inge M., Schalken, Jack A.

“…Samenvatting Om overdiagnostiek en overbehandeling te verminderen, is er dringend behoefte aan een test voor detectie van klinisch significant…”
Get full text